Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Avadel Pharmaceuticals PLC (AVDL)

NASDAQ
Currency in USD
Disclaimer
17.820
+0.160(+0.91%)
Closed
After Hours
18.000+0.180(+1.01%)

AVDL Comments

Lawsuit is a joke, will be $20 plus in 2024
Is it over?
Does anyone think AVDL will surpass 20.oo a share?
It is happening dudes. Brace yourselves
So... what is the bear case? that avadel cant eat market share? Meanwhile it will keep proving doubters wrong
Waaaiit let me buy more!
It's on fire!
it's beginning....👀👀
Buy out by JAZZ?
Once things finaly get going, Avadel will explode. Ten bagger right here
We're back :)
who knows what is happining in the shadows with this company?
Who knows what is happining in the shadows with this company?
Brace yourselves
Huge movements, what the **** is happening D: I like it
"DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th." https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-participate-fireside-chat-10th-annual-svb
what do you think about this one?
im in love with it
gambling...
This is a possible ten bagger if FDA aproves ft218
that was news in Dec
In december they submited to FDA for aproval. It hasn't been aproved yet
What do you think about this stock after Oppenheimer Fall Healthcare of yesterday ?
"Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy"... Pre Market +30-50%
https://www.globenewswire.com/news-release/2019/12/02/1954700/0/en/Avadel-Pharmaceuticals-Announces-Key-Appointments-to-Leadership-Team-To-Support-Continued-Transformation-and-the-Advancement-of-FT218.html
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.